DR. MARIA VALENA FLETCHER MD
Prescription History 1982688024
Family Medicine in Indianapolis, IN

NPI Status: Active since December 02, 2005

Contact Information

2001 W 86TH ST
INDIANAPOLIS, IN
ZIP 46260
Phone: (317) 338-2345

Get Directions

Prescription History for Informed Healthcare Decisions

Explore the verified Medicare Part D prescription history, volume metrics, and calculated drug costs for DR. MARIA VALENA FLETCHER MD, an active Family Medicine specialist practicing in Indianapolis, IN. Our medical registry currently tracks 14 unique pharmaceutical formulations prescribed by this provider, representing an estimated volume of 55,217 documented patient claims. Among these therapy options, the most frequently utilized medication is Shingrix, which accounts for 45,981 claims alone.


Abrysvo

Generic Formulation: Rsv Vacc, Pref A And Pref B/PfSpecialty: Family Practice
Provider Metrics Summary
Total Claims 50
30-Day Fills 50.0
Days Supply 50
IN State Average Benchmarks
Peer Average Claims--
Peer Average 30-Day Fills--
Peer Average Days Supply--

Provider Avg Cost Per Claim

$327.08

State Avg Cost Per Claim

--

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Adacel Tdap

Generic Formulation: Diph,pertuss(Acell),tet Vac/PfSpecialty: Family Practice
Provider Metrics Summary
Total Claims 19
30-Day Fills 19.0
Days Supply 19
IN State Average Benchmarks
Peer Average Claims24.0
Peer Average 30-Day Fills24.1
Peer Average Days Supply147
Standard Average Utilization

This provider's prescribing patterns for this therapeutic formulation sit directly in line with standard baseline averages across IN. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $1,449.89 across this reporting matrix range.

Provider Avg Cost Per Claim

$76.31

State Avg Cost Per Claim

$72.31

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Therapeutic Applications

This vaccine is used to keep up protection (immunity) against diphtheria, tetanus (lockjaw) and pertussis (whooping cough) in children and adults who have been vaccinated for these diseases in the past. It may also be given during the third trimester of pregnancy to help prevent pertussis in the newborn baby. Vaccination is the best way to protect against these life-threatening diseases. Vaccines work by causing the body to produce its own protection (antibodies). Booster doses are needed to keep up immunity because antibody levels may become too low over time to provide the needed protection.

Arexvy

Generic Formulation: Rsvpref3 Antigen/As01e/PfSpecialty: Family Practice
Provider Metrics Summary
Total Claims 467
30-Day Fills 467.0
Days Supply 525
IN State Average Benchmarks
Peer Average Claims--
Peer Average 30-Day Fills--
Peer Average Days Supply--

Provider Avg Cost Per Claim

$322.07

State Avg Cost Per Claim

--

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Boostrix Tdap

Generic Formulation: Diphth,pertuss(Acell),tet VacSpecialty: Family Practice
Provider Metrics Summary
Total Claims 7,780
30-Day Fills 7,784.0
Days Supply 8,396
IN State Average Benchmarks
Peer Average Claims89.0
Peer Average 30-Day Fills89.1
Peer Average Days Supply186
Highly Elevated Utilization

This provider exhibits a high preference for this treatment path, registering a volume 8,641.6% higher than the standard regional baseline profile for IN. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $541,543.65 across this reporting matrix range.

Provider Avg Cost Per Claim

$69.61

State Avg Cost Per Claim

$64.83

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Gardasil 9

Generic Formulation: Hpv Vaccine 9-Valent/PfSpecialty: Family Practice
Provider Metrics Summary
Total Claims 46
30-Day Fills 46.0
Days Supply 46
IN State Average Benchmarks
Peer Average Claims42.0
Peer Average 30-Day Fills42.0
Peer Average Days Supply42
Standard Average Utilization

This provider's prescribing patterns for this therapeutic formulation sit directly in line with standard baseline averages across IN. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $14,491.67 across this reporting matrix range.

Provider Avg Cost Per Claim

$315.04

State Avg Cost Per Claim

$292.62

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Therapeutic Applications

This medication is a vaccine used to prevent cancer of the anus, abnormal tissue growth of the anus, genital warts, or certain head and neck cancers. In girls and women, it is also used to prevent cancer of the cervix/vagina/vulva and abnormal tissue growth in these areas that can lead to cancer. These conditions are commonly caused by certain types of human papillomavirus (HPV). Vaccines work by increasing the body's natural defense (immunity) against the virus. This vaccine does not protect against all types of HPV, only the types in the vaccine. It is used to prevent the diseases and will not treat active anal/cervical/head/neck/vaginal/vulvar cancer, genital warts, or other diseases caused by the types of HPV in the vaccine.

Havrix

Generic Formulation: Hepatitis A Virus Vaccine/PfSpecialty: Family Practice
Provider Metrics Summary
Total Claims 183
30-Day Fills 183.0
Days Supply 270
IN State Average Benchmarks
Peer Average Claims50.0
Peer Average 30-Day Fills50.7
Peer Average Days Supply99
Highly Elevated Utilization

This provider exhibits a high preference for this treatment path, registering a volume 266.0% higher than the standard regional baseline profile for IN. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $19,392.92 across this reporting matrix range.

Provider Avg Cost Per Claim

$105.97

State Avg Cost Per Claim

$99.27

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

Vaccines or candidate vaccines used to prevent infection with hepatitis A virus (HEPATOVIRUS).

Therapeutic Applications

This vaccine is used to help prevent infection from the hepatitis A virus. Hepatitis A infection can be mild with no symptoms or a severe illness that can rarely cause liver failure and death. Preventing infection can prevent these problems. Hepatitis A vaccine is made from whole, killed hepatitis A virus. It does not contain live virus, so you cannot get hepatitis from the vaccine. This vaccine works by helping the body produce immunity (through antibody production) that will prevent you from getting infection from hepatitis A virus. Hepatitis A vaccine does not protect you from other virus infections (such as HIV virus, which causes AIDS; hepatitis B, hepatitis C or hepatitis E; HPV virus, which causes genital warts and other problems). The vaccine is recommended for people aged 12 months and older, especially those at an increased risk of getting the infection. Those at an increased risk include people who live with or spend much time with people with hepatitis A infections, institutional or daycare workers, lab workers, people with multiple sex partners, men who have sex with men, sex workers, injecting and non-injecting drug abusers, and people traveling to high-risk areas.

Heplisav-B

Generic Formulation: Hepatitis B Vaccine/Cpg1018/PfSpecialty: Family Practice
Provider Metrics Summary
Total Claims 13
30-Day Fills 13.0
Days Supply 13
IN State Average Benchmarks
Peer Average Claims--
Peer Average 30-Day Fills--
Peer Average Days Supply--

Provider Avg Cost Per Claim

$160.98

State Avg Cost Per Claim

--

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

M-M-R Ii Vaccine

Generic Formulation: Measles,mumps,rubella Vacc/PfSpecialty: Family Practice
Provider Metrics Summary
Total Claims 20
30-Day Fills 20.0
Days Supply 24
IN State Average Benchmarks
Peer Average Claims23.0
Peer Average 30-Day Fills23.0
Peer Average Days Supply52
Standard Average Utilization

This provider's prescribing patterns for this therapeutic formulation sit directly in line with standard baseline averages across IN. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $2,317.60 across this reporting matrix range.

Provider Avg Cost Per Claim

$115.88

State Avg Cost Per Claim

$112.75

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Therapeutic Applications

This vaccine is used to help prevent serious, sometimes fatal, infections caused by 3 viruses: measles (also known as rubeola), mumps, and rubella (also known as German measles). These are common childhood infections that may cause severe problems (such as deafness, lung/brain problems, or harm to an unborn baby). Preventing these infections through vaccination is very important. This vaccine contains live viruses that have been weakened. It works by causing the body to produce its own protection (antibodies) against the viruses that cause measles, mumps, and rubella.

Menquadfi

Generic Formulation: Mening Vac A,c,y,w135,c-Tet/PfSpecialty: Family Practice
Provider Metrics Summary
Total Claims 26
30-Day Fills 26.0
Days Supply 26
IN State Average Benchmarks
Peer Average Claims--
Peer Average 30-Day Fills--
Peer Average Days Supply--

Provider Avg Cost Per Claim

$188.77

State Avg Cost Per Claim

--

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Naloxone Hcl

Generic Formulation: Naloxone HclSpecialty: Family Practice
Provider Metrics Summary
Total Claims 35
30-Day Fills 35.0
Days Supply 345
IN State Average Benchmarks
Peer Average Claims36.0
Peer Average 30-Day Fills38.3
Peer Average Days Supply313
Standard Average Utilization

This provider's prescribing patterns for this therapeutic formulation sit directly in line with standard baseline averages across IN. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $2,438.35 across this reporting matrix range.

Provider Avg Cost Per Claim

$69.67

State Avg Cost Per Claim

$83.44

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

A specific opiate antagonist that has no agonist activity. It is a competitive antagonist at mu, delta, and kappa opioid receptors.

Therapeutic Applications

This medication is used for the emergency treatment of known or suspected opioid overdose. Serious opioid overdose symptoms may include unusual sleepiness, unusual difficulty waking up, or breathing problems (ranging from slow/shallow breathing to no breathing). Other symptoms of overdose may include very small pinpoint pupils, slow heartbeat, or low blood pressure. If someone has serious overdose symptoms but you are not sure if the symptoms are due to overdose, give this medication right away anyway, since lasting slow/shallow breathing may cause permanent damage to the brain or death. This medication belongs to a class of drugs known as opioid antagonists. It works by blocking the effects of the opioid in the brain. This medication may not work as well to block the effects of certain types of opioids (mixed agonist/antagonists such as buprenorphine, pentazocine). With these types of opioids, blocking may be incomplete or you may need a higher dose of naloxone. The effects of naloxone will not last as long as the effects of the opioid. Since treatment with this medication is not long lasting, be sure to get medical help right away after giving the first dose of naloxone. Treatment of opioid overdose should also include breathing treatment (such as oxygen given through tubes in the nose, mechanical ventilation, artificial respiration).

Shingrix

Generic Formulation: Varicella-Zoster Ge/As01b/PfSpecialty: Family Practice
Provider Metrics Summary
Total Claims 45,981
30-Day Fills 45,990.0
Days Supply 47,152
IN State Average Benchmarks
Peer Average Claims96.0
Peer Average 30-Day Fills96.8
Peer Average Days Supply226
Highly Elevated Utilization

This provider exhibits a high preference for this treatment path, registering a volume 47,796.9% higher than the standard regional baseline profile for IN. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $10,023,966.93 across this reporting matrix range.

Provider Avg Cost Per Claim

$218.00

State Avg Cost Per Claim

$199.08

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Tdvax

Generic Formulation: Tetanus, Diphtheria Tox,adultSpecialty: Family Practice
Provider Metrics Summary
Total Claims 17
30-Day Fills 17.0
Days Supply 17
IN State Average Benchmarks
Peer Average Claims16.0
Peer Average 30-Day Fills16.1
Peer Average Days Supply82
Standard Average Utilization

This provider's prescribing patterns for this therapeutic formulation sit directly in line with standard baseline averages across IN. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $750.82 across this reporting matrix range.

Provider Avg Cost Per Claim

$44.17

State Avg Cost Per Claim

$44.28

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Tenivac

Generic Formulation: Tetanus-Diphtheria Toxoids/PfSpecialty: Family Practice
Provider Metrics Summary
Total Claims 245
30-Day Fills 245.0
Days Supply 274
IN State Average Benchmarks
Peer Average Claims47.0
Peer Average 30-Day Fills47.8
Peer Average Days Supply48
Highly Elevated Utilization

This provider exhibits a high preference for this treatment path, registering a volume 421.3% higher than the standard regional baseline profile for IN. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $14,933.86 across this reporting matrix range.

Provider Avg Cost Per Claim

$60.95

State Avg Cost Per Claim

$57.94

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Therapeutic Applications

This vaccine is used to help prevent problems that may occur with 2 bacterial infections in children and adults (tetanus and diphtheria). Tetanus (lockjaw) and diphtheria can cause serious, sometimes fatal problems (heart problems, nerve problems, muscle paralysis). Vaccination is the best way to protect (provide immunity) against these life-threatening diseases. Vaccines work by getting the body to make its own protection (antibodies). This vaccine is recommended for all people 7 years and older. It should not be used in anyone younger than 7 years because they may not be fully protected by this vaccine. A vaccine for children younger than 7 years is available. Consult your child's health care professional for more information.

Twinrix

Generic Formulation: Hepatitis A And B Vaccine/PfSpecialty: Family Practice
Provider Metrics Summary
Total Claims 335
30-Day Fills 335.0
Days Supply 422
IN State Average Benchmarks
Peer Average Claims79.0
Peer Average 30-Day Fills79.0
Peer Average Days Supply293
Highly Elevated Utilization

This provider exhibits a high preference for this treatment path, registering a volume 324.1% higher than the standard regional baseline profile for IN. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $50,548.14 across this reporting matrix range.

Provider Avg Cost Per Claim

$150.89

State Avg Cost Per Claim

$144.10

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Dataset Methodology & CMS Source Information

This analytical profile maps public infrastructure records sourced directly from official **Centers for Medicare & Medicaid Services (CMS)** public data releases. The statistics above track documented pharmaceutical treatment trends assigned to beneficiaries specifically under federal public programs. Evaluating the prescriptive footprints of clinical practitioners like DR. MARIA VALENA FLETCHER MD provides transparency into local medical care patterns within Indianapolis, IN.

Key Learning Objectives for this Profile:

  • Prescribing Frequencies: Track and evaluate the volume metrics of specific brand-name and generic medical formulas chosen by this provider over time.
  • Clinical Focus Areas: Identify how the provider distributes therapeutic selections across medical care options to gain insight into their true day-to-day **Family Medicine** practice concentrations.
  • Program Cost Awareness: Review the calculated total systemic drug costs and raw transactional volumes linked to these orders to better anticipate network insurance coverage structures.
  • Patient-Centered Evaluation: Cross-reference localized regional care comparisons to align practitioner habits directly with your proactive health maintenance goals.

Data Scope Exclusion & Limitations: The data elements presented above explicitly reflect prescription orders processed for Medicare beneficiaries during the year 2023. This informational profile does not aggregate prescription data for individuals utilizing private commercial health plans, state Medicaid coverage, or self-pay options. However, because medical decision-making remains highly consistent across clinical settings, this public registry provides a reliable proxy for understanding the general prescribing preferences and pharmaceutical care approach used by this provider.